ASH 2023 | Trials of interest in the mantle cell lymphoma space at ASH 2023

Preetesh Jain, MBBS, MD, DM, PhD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses the trials of interest in the area of mantle cell lymphoma (MCL) at the ASH 2023 meeting and comments on the patients who may benefit from the findings of these studies. A Phase II trial of acalabrutinib and rituximab provides a chemotherapy-free option for previously untreated elderly patients (NCT05214183), mosunetuzumab and polatuzumab vedotin were investigated in relapsed/refractory (R/R) MCL (NCT03671018), and 6-year follow-up data was presented from a trial assessing the outcomes of patients receiving ibrutinib and rituximab induction therapy (NCT02427620). A late-breaking abstract of the Phase 3 SYMPATICO (NCT03112174) was also presented, comparing ibrutinib plus venetoclax to ibrutinib plus placebo in R/R MCL. Dr Jain also highlights the importance of the studies which are increasing the depth of knowledge surrounding MCL disease biology, specifically analysing the mechanisms of resistance to BTK inhibitors and CAR T-cell therapy and investigating the high-risk blastoid and pleomorphic MCL variants which confer a poor prognosis. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.